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Abstract
Accurate prediction of drug-target interactions (DTI) enables drug discovery tasks,
including virtual screening and drug repurposing, which can shorten the time to identify
promising drug candidates and provide cures to patients. Recently, there is a growing
number of research that developed deep learning (DL) models for DTI. Despite their
superior performance, these research models are difficult to use in real drug discovery
practice due to the complexity of deploying the research code as well as the restricted
data formatting, model capacity, and evaluation setting. We present DeepPurpose, a
comprehensive and easy-to-use software toolkit for DL based DTI prediction with
applications to drug screening and repurposing. The unique feature of DeepPurpose is
that it enables non-computational drug development scientists to identify drug
candidates based on five pre-trained DL models with only a few lines of codes. Further,
computer scientists can use DeepPurpose to train customized DTI prediction models
with 15 drug and target encodings and 50+ novel DL architectures. To tackle method
development challenges, DeepPurpose also supports various data split settings and
preloads five benchmarking datasets. We demonstrated that DeepPurpose allows users
to obtain state-of-the-art prediction performance on several benchmark datasets. We
also presented several case studies, including a study on drug repurposing for
COVID-19, where promising drug candidates currently investigated in clinical trials are
ranked high in DeepPurpose’s predictions.
Introduction
Drug-target interactions (DTI) characterize the binding of drug molecules to the protein
targets, Accurate identification of DTI is fundamental for drug dis [1–4]. Among others,
drug screening and repurposing are two main applications based on DTI. Drug
screening helps identify ligand candidates that can bind to the protein of interest [5],
whereas drug repurposing finds new therapeutic purposes for existing drugs [6–8]. Both
tasks can alleviate time-consuming and labor-intensive processes in drug development,
which are especially important for finding effective and safe treatments for emerging
pathogens, such as COVID-19 [9].
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Deep learning (DL) has recently demonstrated superior performance than traditional
computational methods because of the expressive power of deep neural networks in
extracting, processing, and extrapolating complex patterns in molecular data [10–13].
For example, an existing study shows they quickly found a drug candidate that could
act against an untreatable strain of bacteria with DL [14]. There are many DL models
designed for DTI prediction [12,13,15], which can be used for drug repurposing and
virtual screening. However, to generate predictions, deploy predictive models in practice,
test and evaluate model performance, and understand model robustness to missing and
incomplete data, one needs to have considerable programming skills and extensive
biochemical knowledge [16,17]. Many existing tools [12,13,15,18] are designed for
computer scientists and are challenging to use by domain researchers with limited
experience in training and deploying deep learning models. Furthermore, each
open-sourced tool has a different programming interface and is coded differently, which
prevents easy integration of outputs from a variety of methods and construction of
multi-model ensembles [19].
In this work, we break the technical barrier by introducing DeepPurpose, a powerful
Python toolkit that can recommend most likely drug candidates. Using only a few code
lines that specify the target amino acid sequences and the drug candidates, DeepPurpose
loads and processes input molecular data, feeds the data into multiple state-of-the-art
deep learning models pre-trained on the large BindingDB-Kd datasets [20] with different
drug and target encoders. DeepPurpose aggregates prediction results and generates a
descriptive ranked list in which drug candidates with the highest predicted binding
scores are placed at the top. This list can then be examined by domain scientists who
inspect the top-ranked drug candidates for downstream experimental validation.
In addition to the design mentioned above for helping domain scientists,
DeepPurpose also offers a flexible framework for computer scientists to innovate new
models for drug-target interaction prediction, expediting repurposing, and screening. In
particular, DeepPurpose includes multiple molecular encoders, including deep neural
networks on classic molecular descriptors from computational biology and
cheminformatics [21–26], a convolutional neural network (CNN) [27], a convolutional
recurrent neural network (CNN-RNN) [28,29], Transformer encoders [30], and
Message-Passing Neural Network (MPNN) [31]. In total, DeepPurpose combines seven
encoders for proteins and eight encoders for drugs and offers over 50 predictive models.
To the best of our knowledge, most encoders and models are novel approaches for drug
interaction prediction. Further, DeepPurpose allows rapid prototyping of new methods
by offering a ten-line programming framework that unlocks new models with a variety
of robust settings for performance evaluation and rigorous method benchmarking
provided by dataset loaders with fixed training/testing splits.
Finally, we conducted extensive experiments to demonstrate that models
implemented in DeepPurpose achieve competitive performance compared to
state-of-the-art baselines. Further, we provided case studies on repurposing for
COVID-19, where DeepPurpose generates promising drug candidates investigated in
clinical trials.
Related Works
Drug Target Interaction Prediction
Computational methods for DTI prediction have received considerable attention in
recent literature. Similarity-based methods, such as kernel regression [32] and matrix
factorization [33], infer new DTI relations by exploiting existing DTI’s drug-target
similarity information. Feature-based methods first generate numerical descriptors for
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drugs [21,34,35] and proteins [23,25,26] and then feed them into downstream prediction
classifiers. The typical classifiers include gradient boosting [36] and random forest [37].
Recently, DL based methods [12,13,15,38] have achieved strong performance because
they can capture intricate non-linear molecular patterns. Notably, DeepDTA uses a
CNN to encode drugs and proteins, and GraphDTA uses graph neural networks to learn
powerful drug encodings.
We formulate deep learning methods for DTI prediction as an encoder-decoder
framework [39], which covers a variety of DTI models, including most of the previous
works. That means that each method has two key components. First, the encoder
component specifies a deep transformation function that maps drugs and proteins to
points in an embedding space, where the structure of the embedding space is optimized
to reflect the structure of the input data. Second, the decoder component takes the
learned drug and protein embeddings and combines them to output the final interaction
activity scores. The encoder-decoder framework is a unifying mathematical formulation
of deep learning methods for DTI prediction. Unlike previous toolkits that only use one
type of encoder for drugs and proteins, DeepPurpose adopts the unifying formulation.
Because of that, DeepPurpose can implement a flexible deep learning framework
integrating 15 encoders, unlocking state-of-the-art methods for DTI prediction.
Deep Learning Libraries for Drug Discovery and Development
Next, we briefly review existing deep learning libraries developed to assist in a variety of
drug discovery and development tasks. Most notably, DeepChem [40] provides a general
framework for life science tasks. MoleculeNet [41] offers a benchmark for drug property
prediction. Similarly, GuacaMol [42] designs a benchmark for de novo molecule
generation and a related library OpenChem (https://github.com/Mariewelt/OpenChem)
is designed for modeling molecules. More relevant to DeepPurpose is a library called
DeepScreening [43] that provides a web interface for in silico drug efficacy screening
using RNN/DNN encoders for drugs. Concurrently, kGCN [44] constructs a GCN-based
framework for DTI prediction. In contrast, DeepPurpose is more powerful since it not
only provides 15 encoders for both drugs and proteins but also presents a user-friendly
interface for both domain researchers and computer scientists.
Design and Implementation
Overview of DeepPurpose
DeepPurpose uses an encoder-decoder framework for drug-target interaction prediction
(Fig 1). Drug repurposing and screening are two important applications of DTI
prediction. DeepPurpose will take the drug’s simplified molecular-input line-entry
system (SMILES) string and target amino acid sequence pair (Fig 2) as input, and
output a score indicating the binding activity of the drug target pair.
Encoders
DeepPurpose provides 8 drug encoders and 7 protein target encoders, ranging from
classic chemical fingerprints to various deep neural networks, each with a variety of
customizable parameters. DeepPurpose feeds the embeddings, returned by the drug and
target encoders into a decoder to produce the final prediction score. As such,
DeepPurpose has a uniquely appealing property in a sense that the user can easily
switch encoders. By specifying the name of the encoder of interest, DeepPurpose
automatically switches to the appropriate model and connects the encoder with the
relevant decoder for prediction.
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Fig 1. DeepPurpose method overview. DeepPurpose takes the accessible drug’s
SMILES string and target’s amino acid sequence and encodes them through one of the
selected 15+ encoder models. Then, the latent representations are concatenated and fed
into a decoder to classify. The model is trained end-to-end and the training process,
along with the test set performance is automatically-generated and reported. For drug
repurposing and virtual screening, given a drug library and a new target of interest or
new drug-target pairs of interest, DeepPurpose feeds them into five pretrained models
and the predictions are aggregated and ranked to generate a drug-target list. This list
can then be used for wet-lab validation. This entire process can be done using one line
of code in DeepPurpose.
Drug Encoders
The input molecule is represented by the SMILES fingerprint [45,46] corresponding to
the relevant molecular graph. DeepPurpose supports the following types of drug
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Fig 2. Input visualization. Drug is represented as a SMILES string and target is
represented as an amino acid sequence. The length distribution of the input is provided.
embeddings that are inferred from the input SMILES fingerprints.
1. Morgan [21] Fingerprint is a 1024-length bits vector that encodes circular
radius-2 substructures. A multi-layer perceptron is then applied to the fingerprint
vector.
2. Pubchem [22] is an 881-length bits vector, where each bit corresponds to an
expert hand-crafted substructure. A multi-layer perceptron is then applied on top
of the vector.
3. Daylight 1 is a 2048-length vector that encodes path-based substructures. A
multi-layer perceptron is then applied on top of the vector.
4. RDKit-2D 2 is a 200-length vector that describes the global pharmacophore
property. It is normalized to make the range of the features on the same scale
using cumulative density function fit given a sample of the molecules.
5. CNN [27] is a multi-layer 1D convolutional neural network. The SMILES
characters are first encoded with an embedding layer and then fed into the CNN
convolutions. A global max-pooling layer is then attached, and an embedding
describing the drug is generated.
6. CNN+RNN [28, 29] attaches a bidirectional recurrent neural network (GRU or
LSTM) on top of the 1D CNN output to leverage the more global temporal
dimension of the drug. The input is also the SMILES character embedding.
7. Transformer [30] uses a self-attention based transformer encoder that operates
on the sub-structure partition fingerprint [43].
8. MPNN [31] is a message-passing graph neural network that operates on the drug
molecular graphs. It transmits latent information among the atoms and edges,
where the input features incorporate atom/edge level chemical descriptors such as
atom/bond type, formal charge, chirality and etc. A readout function (mean/sum)
is used to obtain a molecular graph-level embedding vector.
1Daylight chemical information systems: https://www.daylight.com/
2https: //github.com/bp-kelley/descriptastorus
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Protein Encoders
The input targets are proteins represented by amino acid sequences. DeepPurpose uses
protein sequence information to infer protein embeddings with any of the following
protein encoders:
1. AAC [23] is an 8,420-length vector where each position corresponds to an amino
acid k-mers, which is an amino acid subsequence of length k. The k is up to 3.
2. PseAAC [24] is a 30-length vector that includes the protein hydrophobicity and
hydrophilicity patterns information in addition to the composition.
3. Conjoint Triad [25] is a 343-length descriptor that uses the continuous three
amino acid frequency distribution from a hand-crafted 7 classes (AGV, ILFP,
YMTS, HNQW, RK, DE, C) according to their dipoles and volumes of the side
chains.
4. Quasi Sequence [26] takes account of the sequence order effect using a set of
sequence-order-coupling numbers. Combination of sequence composition and
correlation of physicochemical properties such as hydrophobicity, hydrophilicity,
polarity, and side-chain volume.
5. CNN [27] is a multi-layer 1D convolutional neural network. The target amino
acid is decomposed to each individual character and is encoded with an
embedding layer and then fed into the CNN convolutions. It follows a global
max-pooling layer.
6. CNN+RNN [29, 39] attaches a bidirectional recurrent neural network (GRU or
LSTM) on top of the 1D CNN output to leverage the sequence order information.
7. Transformer [30] uses a self-attention based transformer encoder that operates
on the sub-structure partition fingerprint [47] of proteins. Since the transformer’s
computation time and memory is quadratic on the input size, it is
computationally infeasible to treat each amino acid symbol as a token. The
partition fingerprint decomposes amino acid sequence into protein substructures of
moderate-sized such as motifs and then each of the partitions is considered as a
token and fed into the model.
Decoders, Objective functions, and Model Inference
The generated drug and protein embeddings will be fed into a multi-layer perceptron
decoder. There are two classes of tasks/datasets in DTI prediction. The label can be
either continuous binding scores, including Kd and IC50, or a binary output indicating
whether they can bind. DeepPurpose can automatically detect whether the task is a
regression for continuous label or classification for the binary label by counting the
number of unique labels in the data. For binding affinity score prediction, the training
uses mean squared error (MSE) loss; for binary interaction prediction, it uses binary
cross-entropy (BCE) loss:
LMSE = 1
n
n∑
i=1
(yi − yˆi)2, (1)
LBCE = 1
n
n∑
i=1
yilog(yˆi) + (1− yi)log(1− yˆi), (2)
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where yi is the true label and yˆi is the predicted label for i-th drug-target pair. For
evaluation, the following metrics are included: MSE, Concordance Index, and Pearson
Correlation for continuous regression and Receiver Operating Characteristics-Area
Under the Curve (ROC-AUC), Precision Recall-Area Under the Curve (PR-AUC) and
F1 score at threshold 0.5 for binary classification. During inference, given new targets
or new drugs, the model prediction is used as the predicted binding score/interaction
probability.
Applications to Drug Repurposing and Drug Efficacy Screening
After the models are trained from the DTI prediction datasets, they can be used to do
drug repurposing and screening since the model is able to capture the chemical
knowledge to infer a new drug-target pair’s binding affinity. For drug repurposing, given
a new target protein and a drug repurposing library, which is an array of approved
drugs, DeepPurpose replicates the target and form drug-target pairs, which are then fed
into the model for inference. In the case of drug efficacy screening, given many
drug-target pairs, we directly feed them into the model, which, in turn, produces output
prediction scores.
Pretrained Models and Prediction Aggregation
DeepPurpose includes over 20 pre-trained models. This is important because deep
learning models require considerable computational resources for training. Thus,
providing a pre-trained model that does not need to be trained from scratch can
significantly reduce the time and resources needed for deploying the model in a
real-world application. Using a pre-trained model is also desirable for a new target with
a low amount of training data since it could benefit from the knowledge transferred via
models learned from massive data [48]. Unlike most previous works that mainly rely on
a single model for prediction, DeepPurpose integrates many encoders in one framework
and ensemble multiple models for repurposing and virtual screening. Such an
multi-model approach can greatly reduce the limitation and bias brought forward by
any individual model, albeit a well-performing approach. DeepPurpose includes three
aggregation strategies: mean, max, and the average of mean and max. The mean
measures the overall performance across models, while the max favors the most reliable
signals across all models. To leverage both approaches, we also include an aggregation
scheme that takes the average of mean and max. For the one-line default mode for
domain scientists, we use the latter option.
One-Line Mode for Drug Repurposing and Screening
For biomedical scientists, DeepPurpose provides a one-line mode that only requires the
target protein amino acid sequences and the drug candidates’ inputs. Then,
DeepPurpose uses five pretrained models trained on large BindingDB datasets and
applies a mean-max aggregation scheme to ensemble the prediction result. The result
binding scores are ranked, and the top drug-target pairs are retrieved. The entire
pipeline happens in one line. A sample code is illustrated in Fig 3.
The five pretrained models defined in the default One-Line mode are listed below:
1. MPNN for drugs and CNN for proteins;
2. CNN for drug and CNN for proteins;
3. Daylight for drugs and AAC for proteins;
4. Morgan fingerprint for drugs and AAC for proteins;
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Fig 3. DeepPurpose programming framework illustration. A. Generate a drug
candidate list using a one-line mode for non-computational researchers. B. A 10-lines
framework for machine learning method researchers.
5. Morgan fingerprint for drugs and CNN for proteins.
The above-pretrained model architectures are selected based on the following
principles.
• The pretrained models should have literature support, i.e., GraphDTA [15] (Graph
Neural Network+CNN) for model 1 and DeepDTA [12] (CNN+CNN) for model 2;
• The models should include classic informatics embedding since they sometimes
contain more global information that deep learning-based methods may miss [19]
(Morgan+AAC, Daylight+AAC) as model 3 and model 4;
• A hybrid model between DL based method and classic embeddings
(Morgan+CNN) as model 5. We omit transformers and CNN-RNN based methods
due to the consideration that pretrained models need to be relatively lightweight
for deployment.
Framework for Drug-Target Interaction Prediction
For computer scientists, DeepPurpose provides a 10-lines framework that accepts
user-customized information to conduct method research. For example, it enables easy
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switching of different encoders, supports customized data split such as cold drug setting,
and allows almost any model parameters or optimizer hyperparameters. A sample code
is illustrated in Fig 3.
Additional Functionalities
DeepPurpose provides several additional functions that can aid users in drug
repurposing and virtual screening. First, DeepPurpose provides many types of data:
public large binding affinity dataset such as BindingDB-Kd [20], KIBA [36], DAVIS [49];
bioassay data such as AID1706 for SARS-CoV 3CL Protease; repurposing library such
as Broad Repurposing Hub [50], antiviral drugs; target proteins such as SARS-CoV2
3CL Protease, Helicase, endoRNAse, etc. This can save users valuable time since the
data sources are scattered and information to process the raw data is limited online.
With one line of code, DeepPurpose downloads and preprocesses the dataset to
downstream models’ compatible input. We also provide data loading functions from
users’ txt files. Second, binding affinity scores such as Kd, IC50 is recorded in the nM
unit. However, the label distribution is very skewed. Hence, DeepPurpose also provides
a convert unit function that can transform the label unit to log-scale for easy regression
and also convert back when doing repurposing and virtual screening. Third, some
classic encoders require some preprocessing time. DeepPurpose provides a reference
time to help users estimate the computing hours. Fourth, DeepPurpose supports
Bayesian Optimization hyperparameter tuning. Fifth, DeepPurpose takes the input of
only one drug to model screening data for a target that does not have protein sequence
format, such as bacteria.
Results
We conduct three experiments to evaluate DeepPurpose.
Predictive Performance on Drug-Target Interaction Prediction
First, we demonstrate that various models in DeepPurpose achieve competitive
performance against state-of-the-art DL models for DTI prediction tasks on two
benchmark datasets, DAVIS [49], and KIBA [36]. We compare it with DeepDTA [12],
GraphDTA [15], two state-of-the-art DL models, and KronRLS [32], a classic method.
Since DAVIS and KIBA are binding scores, the evaluation metric is MSE and
Concordance Index. We use 7:1:2 train: validation: test splits. Dataset statistics are
provided in Table 1.
Table 1. Data Statistics.
Dataset Num. of Drugs Num. of Proteins Num. of Interactions
DAVIS [49] 68 379 30,056
KIBA [36] 2,068 229 118,254
BindingDB-Kd [20] 13,349 1,658 74,641
We report the performances of seven DeepPurpose models and three state-of-the-art
models for DTI prediction on DAVIS and KIBA in Table 2. We find that DeepPurpose
achieves competitive performance on all metrics on both datasets, confirming its
powerful performance. Specifically, we find using MPNN for drugs and AAC for target
proteins achieve the best result in both datasets. It has 7.6% increase in MSE, 1.3%
increase in concordance index for DAVIS dataset and 2.8% increase in MSE, 1.2%
increase in concordance index for KIBA dataset over the best baseline.
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Table 2. Drug target interaction predictive performance on benchmark
datasets. The bottom seven methods are from DeepPurpose. Results
reported with five dataset splits average and standard deviation. Note that
all models including the baselines run on the same five data splits to
ensure fair comparison.
Dataset 1: DAVIS
Model MSE Concordance Index
Baselines
KronRLS 0.329 (0.019) 0.847 (0.006)
GraphDTA 0.263 (0.015) 0.864 (0.007)
DeepDTA 0.262 (0.022) 0.870 (0.003)
DeepPurpose
CNN+CNN 0.254 (0.018) 0.879 (0.011)
MPNN+CNN 0.271 (0.012) 0.858 (0.007)
MPNN+AAC 0.242 (0.009) 0.881 (0.005)
CNN+Trans 0.282 (0.009) 0.852 (0.006)
Morgan+CNN 0.271 (0.012) 0.858 (0.007)
Morgan+AAC 0.258 (0.012) 0.861 (0.008)
Daylight+AAC 0.277 (0.014) 0.861 (0.008)
Dataset 2: KIBA
Model MSE Concordance Index
Baselines
KronRLS 0.852 (0.014) 0.688 (0.003)
GraphDTA 0.183 (0.003) 0.862 (0.005)
DeepDTA 0.196 (0.008) 0.864 (0.002)
DeepPurpose
CNN+CNN 0.196 (0.005) 0.856 (0.004)
MPNN+CNN 0.222 (0.006) 0.825 (0.003)
MPNN+AAC 0.178 (0.002) 0.872 (0.001)
CNN+Trans 0.240 (0.013) 0.818 (0.004)
Morgan+CNN 0.229 (0.008) 0.825 (0.004)
Morgan+AAC 0.233 (0.009) 0.823 (0.004)
Daylight+AAC 0.252 (0.014) 0.808 (0.008)
Prediction Evaluation for Pretrained Models in One-Line Mode
Second, we observe that DAVIS and KIBA are high throughput screening data, and the
unique number of proteins and targets is small. Due to the small size, models trained on
these two datasets are not ideal for generalization over unseen drugs and proteins,
especially for what we need for the one-line pretrained model. We thus use pre-trained
models that are trained on a large BindingDB-Kd dataset, which consists of 1,413
proteins and 10,665 drugs. To evaluate the predictive efficacy of each pre-training
model used in the one-line mode, we report the predictive performance on the test set in
Table 3. We see all five models achieve high performance on all metrics in the test set
for the BindingDB-Kd dataset.
Table 3. Predictive performance of pretraining models on the
BindingDB-Kd dataset. Five fold average and standard deviation of the
test set performance is reported.
DeepPurpose Model MSE Concordance Index
MPNN+CNN 0.635 (0.014) 0.841 (0.004)
CNN+CNN 0.600 (0.007) 0.857 (0.003)
Morgan+CNN 0.631 (0.002) 0.846 (0.005)
Morgan+AAC 0.629 (0.034) 0.848 (0.005)
Daylight+AAC 0.649 (0.014) 0.841 (0.004)
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In many cases, the users may use drug-target pairs that are different from the
training dataset. To test the model’s generalizability, we test on the DAVIS dataset,
which has zero overlaps with the pretraining BindingDB-Kd dataset. We then sample
1,000 unseen drug-target pairs from DAVIS and feed them into the pretrained models
and report the Pearson correlation between the true and predicted binding scores. We
find the predicted Kd values of DeepPurpose are highly correlated with the true values
with Pearson correlation 0.7789 (Fig 4), indicating the reliable predictions from
DeepPurpose, even on new data. This result suggests the high-quality prediction for
unseen data, making the pretrained models ideal for one-line default usage.
Fig 4. DeepPurpose pretrained models aggregation are able to generalize
over unseen dataset. This finding validates that one-line pre-trained models can be
used by drug developers to quickly generate a list of potential drug candidates.
Case Study on Drug Repurposing for COVID-19
Third, we conduct two case studies to showcase the easy usage of DeepPurpose for
biomedical researchers. In the first case, suppose a biomedical researcher wants to
identify which existing antiviral drugs can be repurposed to target SARS-CoV2 3CL
Protease (3CLPro). With only one line of code, DeepPurpose aggregates multiple
pretrained models and outputs top-ranked antiviral drug candidates. We present the
results in Fig 5. Out of the 81 antiviral drugs in the library, DeepPurpose recommends
13 potentially active drugs that have Kd values within 500 [51] units. We conduct a
literature search for the 13 drugs and find that Ritonavir, Darunavir, Lopinavir are three
of a few drug candidates that are currently undergoing clinical trials for SARS-CoV2-
3CLPro [52–54]. The top recommended drug Sofosbuvir is an anti-HCV protein
inhibitor and is currently undergoing many in-vitro investigations for its potential usage
for COVID19 [55]. Some other molecular docking studies also reported the potential
efficacy of Simeprevir [56] and Amantadine [57]. Overall, 6 recommendations out of 13
have promising evidence based on literature or clinical trials, which confirms the
potential of DeepPurpose for suggesting high-quality repurposing candidates.
Next, we illustrate the flexibility of DeepPurpose for a more customized biomedical
use case. We still consider the 3CL Protease for repurposing for COVID-19. However, in
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Fig 5. DeepPurpose identifies drug candidates in ongoing clinical trials for
COVID-19. Using one line of code, given the amino acid sequence of
SARS-CoV2-3CLPro target, and a list of SMILES strings of an antiviral drug library,
DeepPurpose aggregates from five pretrained models and generates a ranked list, where
drugs that have top predicted binding scores are displayed. We conduct literature
search and discover that the top ranked drugs are in ongoing clinical trials for
COVID-19. Note that DeepPurpose only uses the chemical structures of target and
drugs, without any information about existing ongoing clinical trials. The clinical trials
information is only used to validate the utility of our methods.
this case, a biomedical scientist wants to train a deep learning model from past bioassay
data such as high throughput screening (HTS) assay on SARS-CoV 3CL Protease [34],
which conserves large portion of the gene with SARS-CoV-2. This is potentially a better
training dataset than the general BindingDB-Kd dataset for COVID-19. Specifically,
DeepPurpose takes the customized training dataset as input and trains multiple DL
models using this assay data to score drug candidates from the antiviral library or any
proprietary data. This resulting candidate list has support from the literature. We find
that most of them are protein synthesis inhibitors, which is consistent with the general
3CLPro inhibition mechanism. Specifically, in addition to Ritonavir, it surprisingly
outputs Remdesivir with high confidence, which is a star candidate for COVID19 by
blocking the RNA polymerase and has shown initial clinical effects [58]. There are also
initial literature evidence or clinical trials for Tipranavir [59], Methisazone [60],
Baloxavir [61], Indinavir [60] to tackle COVID-19. Since this bioassay has a binary label,
DeepPurpose automatically switches from regression for binding affinity to binary
classification by using different loss functions. The use case is illustrated in Fig 6.
Availability and Future Works
All scripts, datasets, and models are described and open-sourced online at
https://github.com/kexinhuang12345/DeepPurpose. The related documentation is
located at https://deeppurpose.readthedocs.io/en/latest/. We also provide
numerous tutorials, demos, and blogs to aid user usage in the repository.
DeepPurpose is a python package with a Jupyter Notebook interface. It can run
locally to ease the concern of processing proprietary drug data. It can also run on the
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Fig 6. Repurposing using customized training data in one line of code .
Still using one line of code, DeepPurpose is able to take in customized training data,
such as AID1706 bioassay data in this case and train five new models to generate a drug
candidate list. The ROC-AUC and PR-AUC curves are automatically generated and
they compare different training model’s predictive performance.
cloud, which alleviates the computational resource burdens faced by some users.
DeepPurpose is OS-agnostic.
In the future, we plan to increase its capabilities by potentially including more
models, adding more functionalities such as interpretability, and expanding to more
biomedical therapeutic entities such as antibody.
Discussion
DeepPurpose has several advantages over other DTI prediction pipelines. First,
DeepPurpose is user-friendly. DeepPurpose is a python package with a Jupyter
Notebook interface. It can run locally to ease the concern of processing proprietary
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drug data. It can also run on the cloud, which alleviates the computational resource
burdens faced by some users. For biomedical researchers, it allows one line of code to
unlock state-of-the-art deep learning and apply it to any target protein of interest for
drug repurposing and virtual screening. For computer scientists, DeepPurpose provides
a 10-line programming framework that can be adapted to any neural architecture and
can expedite the development of new computational methods. We also provide tutorials,
demos, and documentation to aid user usage. It also bears different user demands and
has a variety of features, including model robustness evaluation by cold-drug/target
splits, customized training datasets such as high throughput screening data, and
screening for non-protein targets such as bacteria.
Second, DeepPurpose is powerful. It incorporates 7 encoders for proteins, 8 encoders
for drugs, over 50 state-of-the-art deep learning models, over 20 pre-trained models
trained on large benchmark datasets, and over 5 benchmark datasets loaders. By
implementing them in the same framework, DeepPurpose also allows flexibility in using
different encoders algorithms (i.e., input representations). This could broaden the
search horizons and catch drugs that were missed by existing works due to the bias from
only using one particular encoder model.
Conclusion
We propose a powerful, user-friendly, and general framework for drug-target interaction
prediction. We envision that DeepPurpose will increase the accessibility of deep learning
for drug discovery and create valuable insights that can benefit patients. DeepPurpose
is an open-source project, and we call for both domain scientists and computational
researchers to contribute to it.
References
1. Srivastava PK, van Eyll J, Godard P, Mazzuferi M, Delahaye-Duriez A,
Van Steenwinckel J, et al. A systems-level framework for drug discovery identifies
Csf1R as an anti-epileptic drug target. Nature Communications. 2018;9(1):3561.
doi:10.1038/s41467-018-06008-4.
2. Deans RM, Morgens DW, O¨kesli A, Pillay S, Horlbeck MA, Kampmann M, et al.
Parallel shRNA and CRISPR-Cas9 screens enable antiviral drug target
identification. Nature Chemical Biology. 2016;12(5):361–366.
doi:10.1038/nchembio.2050.
3. Rutkowska A, Thomson DW, Vappiani J, Werner T, Mueller KM, Dittus L, et al.
A Modular Probe Strategy for Drug Localization, Target Identification and
Target Occupancy Measurement on Single Cell Level. ACS Chemical Biology.
2016;11(9):2541–2550. doi:10.1021/acschembio.6b00346.
4. Zitnik M, Nguyen F, Wang B, Leskovec J, Goldenberg A, Hoffman MM. Machine
learning for integrating data in biology and medicine: Principles, practice, and
opportunities. Information Fusion. 2019;50:71–91.
doi:10.1016/j.inffus.2018.09.012.
5. Shoichet BK. Virtual screening of chemical libraries. Nature.
2004;432(7019):862–865. doi:10.1038/nature03197.
6. Cheng F, Zhao J, Fooksa M, Zhao Z. A network-based drug repositioning
infrastructure for precision cancer medicine through targeting significantly
July 14, 2020 14/19
mutated genes in the human cancer genomes. Journal of the American Medical
Informatics Association. 2016;23(4):681–691. doi:10.1093/jamia/ocw007.
7. Xu H, Aldrich MC, Chen Q, Liu H, Peterson NB, Dai Q, et al. Validating drug
repurposing signals using electronic health records: a case study of metformin
associated with reduced cancer mortality. Journal of the American Medical
Informatics Association. 2015;22(1):179–191. doi:10.1136/amiajnl-2014-002649.
8. Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug
repurposing: progress, challenges and recommendations. Nature Reviews Drug
Discovery. 2019;18(1):41–58. doi:10.1038/nrd.2018.168.
9. Velavan TP, Meyer CG. The COVID19 epidemic. Tropical Medicine &
International Health. 2020;25(3):278–280. doi:10.1111/tmi.13383.
10. Cheng F, Zhao Z. Machine learning-based prediction of drug–drug interactions by
integrating drug phenotypic, therapeutic, chemical, and genomic properties.
Journal of the American Medical Informatics Association. 2014;21(e2):e278–e286.
doi:10.1136/amiajnl-2013-002512.
11. Fathiamini S, Johnson AM, Zeng J, Araya A, Holla V, Bailey AM, et al.
Automated identification of molecular effects of drugs (AIMED). Journal of the
American Medical Informatics Association. 2016;23(4):758–765.
doi:10.1093/jamia/ocw030.
12. O¨ztu¨rk H, O¨zgu¨r A, Ozkirimli E. DeepDTA: deep drug–target binding affinity
prediction. Bioinformatics. 2018;34(17):i821–i829.
doi:10.1093/bioinformatics/bty593.
13. Lee I, Keum J, Nam H. DeepConv-DTI: Prediction of drug-target interactions
via deep learning with convolution on protein sequences. PLOS Computational
Biology. 2019;15(6):e1007129. doi:10.1371/journal.pcbi.1007129.
14. Stokes JM, Yang K, Swanson K, Jin W, Cubillos-Ruiz A, Donghia NM, et al. A
Deep Learning Approach to Antibiotic Discovery. Cell. 2020;180(4):688–702.e13.
doi:10.1016/j.cell.2020.01.021.
15. Nguyen T, Le H, Quinn TP, Le T, Venkatesh S. GraphDTA: Predicting
drug–target binding affinity with graph neural networks. bioRxiv. 2020; p.
684662. doi:10.1101/684662.
16. Soysal E, Wang J, Jiang M, Wu Y, Pakhomov S, Liu H, et al. CLAMP – a
toolkit for efficiently building customized clinical natural language processing
pipelines. Journal of the American Medical Informatics Association.
2018;25(3):331–336. doi:10.1093/jamia/ocx132.
17. Brown AS, Patel CJ. MeSHDD: Literature-based drug-drug similarity for drug
repositioning. Journal of the American Medical Informatics Association.
2017;24(3):614–618. doi:10.1093/jamia/ocw142.
18. Tsubaki M, Tomii K, Sese J. Compound–protein interaction prediction with
end-to-end learning of neural networks for graphs and sequences. Bioinformatics.
2019;35(2):309–318.
19. Yang K, Swanson K, Jin W, Coley C, Eiden P, Gao H, et al. Analyzing Learned
Molecular Representations for Property Prediction. Journal of Chemical
Information and Modeling. 2019;59(8):3370–3388. doi:10.1021/acs.jcim.9b00237.
July 14, 2020 15/19
20. Liu T, Lin Y, Wen X, Jorissen RN, Gilson MK. BindingDB: a web-accessible
database of experimentally determined protein–ligand binding affinities. Nucleic
Acids Research. 2007;35(suppl 1):D198–D201. doi:10.1093/nar/gkl999.
21. Rogers D, Hahn M. Extended-Connectivity Fingerprints. Journal of Chemical
Information and Modeling. 2010;50(5):742–754. doi:10.1021/ci100050t.
22. Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, et al. PubChem 2019 update:
improved access to chemical data. Nucleic Acids Research.
2019;47(D1):D1102–D1109. doi:10.1093/nar/gky1033.
23. Reczko M, Bohr H. The DEF data base of sequence based protein fold class
predictions. Nucleic Acids Research. 1994;22(17):3616–3619.
24. Chou KC. Using amphiphilic pseudo amino acid composition to predict enzyme
subfamily classes. Bioinformatics. 2005;21(1):10–19.
doi:10.1093/bioinformatics/bth466.
25. Shen J, Zhang J, Luo X, Zhu W, Yu K, Chen K, et al. Predicting protein–protein
interactions based only on sequences information. Proceedings of the National
Academy of Sciences of the United States of America. 2007;104(11):4337–4341.
doi:10.1073/pnas.0607879104.
26. Chou KC. Prediction of protein subcellular locations by incorporating
quasi-sequence-order effect. Biochemical and Biophysical Research
Communications. 2000;278(2):477–483. doi:10.1006/bbrc.2000.3815.
27. Krizhevsky A, Sutskever I, Hinton GE. ImageNet Classification with Deep
Convolutional Neural Networks. In: Pereira F, Burges CJC, Bottou L,
Weinberger KQ, editors. Advances in Neural Information Processing Systems 25.
Curran Asso-
ciates, Inc.; 2012. p. 1097–1105. Available from: http://papers.nips.cc/paper/
4824-imagenet-classification-with-deep-convolutional-neural-networks.
pdf.
28. Cho K, van Merrie¨nboer B, Gulcehre C, Bahdanau D, Bougares F, Schwenk H,
et al. Learning Phrase Representations using RNN Encoder–Decoder for
Statistical Machine Translation. In: Proceedings of the 2014 Conference on
Empirical Methods in Natural Language Processing (EMNLP). Doha, Qatar:
Association for Computational Linguistics; 2014. p. 1724–1734. Available from:
https://www.aclweb.org/anthology/D14-1179.
29. Hochreiter S, Schmidhuber J. Long Short-Term Memory. Neural Computation.
1997;9(8):1735–1780. doi:10.1162/neco.1997.9.8.1735.
30. Vaswani A, Shazeer N, Parmar N, Uszkoreit J, Jones L, Gomez AN, et al.
Attention is All you Need. In: Guyon I, Luxburg UV, Bengio S, Wallach H,
Fergus R, Vishwanathan S, et al., editors. Advances in Neural Information
Processing Systems 30. Curran Associates, Inc.; 2017. p. 5998–6008. Available
from:
http://papers.nips.cc/paper/7181-attention-is-all-you-need.pdf.
31. Gilmer J, Schoenholz SS, Riley PF, Vinyals O, Dahl GE. Neural Message Passing
for Quantum Chemistry. In: International Conference on Machine Learning; 2017.
p. 1263–1272. Available from:
http://proceedings.mlr.press/v70/gilmer17a.html.
July 14, 2020 16/19
32. Pahikkala T, Airola A, Pietila¨ S, Shakyawar S, Szwajda A, Tang J, et al. Toward
more realistic drug–target interaction predictions. Briefings in Bioinformatics.
2015;16(2):325–337. doi:10.1093/bib/bbu010.
33. Zheng X, Ding H, Mamitsuka H, Zhu S. Collaborative matrix factorization with
multiple similarities for predicting drug-target interactions. In: Proceedings of
the 19th ACM SIGKDD international conference on Knowledge discovery and
data mining - KDD ’13. Chicago, Illinois, USA: ACM Press; 2013. p. 1025.
Available from: http://dl.acm.org/citation.cfm?doid=2487575.2487670.
34. PubChem. AID 1706 - QFRET-based primary biochemical high throughput
screening assay to identify inhibitors of the SARS coronavirus 3C-like Protease
(3CLPro);. Available from:
https://pubchem.ncbi.nlm.nih.gov/bioassay/1706.
35. Winter R, Montanari F, Noe´ F, Clevert DA. Learning continuous and data-driven
molecular descriptors by translating equivalent chemical representations.
Chemical science. 2019;10(6):1692–1701.
36. He T, Heidemeyer M, Ban F, Cherkasov A, Ester M. SimBoost: a read-across
approach for predicting drug–target binding affinities using gradient boosting
machines. Journal of Cheminformatics. 2017;9. doi:10.1186/s13321-017-0209-z.
37. Shi H, Liu S, Chen J, Li X, Ma Q, Yu B. Predicting drug-target interactions
using Lasso with random forest based on evolutionary information and chemical
structure. Genomics. 2019;111(6):1839–1852. doi:10.1016/j.ygeno.2018.12.007.
38. Kim P, Winter R, Clevert DA. Deep Protein-Ligand Binding Prediction Using
Unsupervised Learned Representations. 2020;doi:10.26434/chemrxiv.11523117.v1.
39. Cho K, van Merrie¨nboer B, Bahdanau D, Bengio Y. On the Properties of Neural
Machine Translation: Encoder–Decoder Approaches. In: Proceedings of SSST-8,
Eighth Workshop on Syntax, Semantics and Structure in Statistical Translation.
Doha, Qatar: Association for Computational Linguistics; 2014. p. 103–111.
Available from: https://www.aclweb.org/anthology/W14-4012.
40. Ramsundar B, Eastman P, Walters P, Pande V. Deep Learning for the Life
Sciences: Applying Deep Learning to Genomics, Microscopy, Drug Discovery, and
More. ”O’Reilly Media, Inc.”; 2019.
41. Wu Z, Ramsundar B, N Feinberg E, Gomes J, Geniesse C, S Pappu A, et al.
MoleculeNet: a benchmark for molecular machine learning. Chemical Science.
2018;9(2):513–530. doi:10.1039/C7SC02664A.
42. Brown N, Fiscato M, Segler MHS, Vaucher AC. GuacaMol: Benchmarking
Models for de Novo Molecular Design. Journal of Chemical Information and
Modeling. 2019;59(3):1096–1108. doi:10.1021/acs.jcim.8b00839.
43. Liu Z, Du J, Fang J, Yin Y, Xu G, Xie L. DeepScreening: a deep learning-based
screening web server for accelerating drug discovery. Database: The Journal of
Biological Databases and Curation. 2019;2019. doi:10.1093/database/baz104.
44. Kojima R, Ishida S, Ohta M, Iwata H, Honma T, Okuno Y. kGCN: a
graph-based deep learning framework for chemical structures. Journal of
Cheminformatics. 2020;12(1):32. doi:10.1186/s13321-020-00435-6.
July 14, 2020 17/19
45. Weininger D. SMILES, a chemical language and information system. 1.
Introduction to methodology and encoding rules. Journal of Chemical
Information and Computer Sciences. 1988;28(1):31–36. doi:10.1021/ci00057a005.
46. Weininger D, Weininger A, Weininger JL. SMILES. 2. Algorithm for generation
of unique SMILES notation. Journal of Chemical Information and Modeling.
1989;29(2):97–101. doi:10.1021/ci00062a008.
47. Huang K, Xiao C, Hoang TN, Glass LM, Sun J. CASTER: Predicting Drug
Interactions with Chemical Substructure Representation. Proceedings of AAAI
Conference on Artificial Intelligence. 2020;.
48. Pan SJ, Yang Q. A Survey on Transfer Learning. IEEE Transactions on
Knowledge and Data Engineering. 2010;22(10):1345–1359.
doi:10.1109/TKDE.2009.191.
49. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, et al.
Comprehensive analysis of kinase inhibitor selectivity. Nature Biotechnology.
2011;29(11):1046–1051. doi:10.1038/nbt.1990.
50. Corsello SM, Bittker JA, Liu Z, Gould J, McCarren P, Hirschman JE, et al. The
Drug Repurposing Hub: a next-generation drug library and information resource.
Nature Medicine. 2017;23(4):405–408. doi:10.1038/nm.4306.
51. Beck BR, Shin B, Choi Y, Park S, Kang K. Predicting commercially available
antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a
drug-target interaction deep learning model. Computational and Structural
Biotechnology Journal. 2020;18:784–790. doi:10.1016/j.csbj.2020.03.025.
52. Harrison C. Coronavirus puts drug repurposing on the fast track. Nature
Biotechnology. 2020;38(4):379–381. doi:10.1038/d41587-020-00003-1.
53. Deng L. A randomised, open, controlled trial for darunavir/cobicistat or
Lopinavir/ritonavir combined with thymosin a1 in the treatment of novel
coronavirus pneumonia (COVID-19); 2020.
54. Lu H. Efficacy and Safety of Darunavir and Cobicistat for Treatment of
COVID-19; 2020. Available from:
https://clinicaltrials.gov/ct2/show/NCT04252274.
55. McCreary EK, Pogue JM. Coronavirus Disease 2019 Treatment: A Review of
Early and Emerging Options. Open Forum Infectious Diseases. 2020;7(4).
doi:10.1093/ofid/ofaa105.
56. Hosseini FS, Amanlou M. Simeprevir, Potential Candidate to Repurpose for
Coronavirus Infection: Virtual Screening and Molecular Docking Study.
2020;doi:10.20944/preprints202002.0438.v1.
57. Cimolai N. Potentially repurposing adamantanes for COVID-19. Journal of
Medical Virology. 2020;doi:10.1002/jmv.25752.
58. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al.
Compassionate Use of Remdesivir for Patients with Severe Covid-19. The New
England Journal of Medicine. 2020;doi:10.1056/NEJMoa2007016.
59. Dayer MR. Old Drugs for Newly Emerging Viral Disease, COVID-19:
Bioinformatic Prospective. arXiv:200304524 [q-bio]. 2020;.
July 14, 2020 18/19
60. Shah B, Modi P, Sagar SR. In silico studies on therapeutic agents for COVID-19:
Drug repurposing approach. Life Sciences. 2020;252:117652.
doi:10.1016/j.lfs.2020.117652.
61. Shentu J. Randomized, open-label, controlled trial for evaluating of the efficacy
and safety of Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir in the
treatment of novel coronavirus pneumonia (COVID-19) patients;. Available from:
http://www.chictr.org.cn/showprojen.aspx?proj=49015.
July 14, 2020 19/19
